The Financial Express21d
NCCN Guidelines recognises Novartis’ ribociclib as Category 1 preferred breast cancer adjuvant treatment
Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...
BioSpace24d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Kisqali ® (ribociclib) is a selective cyclin-dependent kinase inhibitor ... Low white blood cell counts (neutropenia). Low white blood cell counts are very common during treatment with KISQALI and may ...
Novartis27d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...